Your browser doesn't support javascript.
loading
Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis.
Mian, Agrima; Naqvi, Syed Arsalan Ahmed; Ayaz, Ahsan; Husnain, Muhammad; Aljama, Mohammed A; Mohyuddin, Ghulam Rehman; Koehn, Kelly; Mohan, Meera; Bin Riaz, Irbaz; Chakraborty, Rajshekhar.
Afiliación
  • Mian A; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
  • Naqvi SAA; Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA.
  • Ayaz A; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Husnain M; University of Arizona Cancer Center, Tucson, AZ, USA.
  • Aljama MA; Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
  • Mohyuddin GR; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Koehn K; Department of Hematological Malignancies, Kansas University Medical Center, Kansas City, KS, USA.
  • Mohan M; Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Bin Riaz I; Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Chakraborty R; Herbert Irving Comprehensive Cancer Center, Columbia University, NY, USA. Electronic address: rc3360@cumc.columbia.edu.
Leuk Res ; 131: 107324, 2023 08.
Article en En | MEDLINE | ID: mdl-37285641
Anti-CD38 monoclonal antibodies (mAbs) are commonly used for treating newly diagnosed and relapsed/refractory (r/r) multiple myeloma (MM). However, concerns have been raised about the occurrence of second primary malignancies (SPMs) in patients receiving anti-CD38 mAbs. Assessing the safety data for rare adverse events like SPMs is challenging because individual clinical trials are typically focused on the primary endpoint. Therefore, we conducted a meta-analysis of randomized controlled trials (RCTs) published between January 2005 and April 2022, including patients with newly diagnosed or r/r MM. Our aim was to compare SPM rate with the use of anti-CD38 mAb-based regimens with other anti-myeloma regimens. After a median follow-up of 35.3 months (range: 8.2-56.2), we found that exposure to anti-CD38 mAbs was associated with an increased risk of developing SPMs compared to the control group (6.8% vs. 5.2%; Peto odds ratio [OR]: 1.53 [95% confidence interval (CI): 1.20-1.95]; I2= 0%, p-value for heterogeneity= 0.44). This increased risk was primarily driven by non-melanoma cutaneous cancers (92 vs. 47; Peto OR: 1.77 [95% CI: 1.25-2.51]; I2 = 0%, p-value for heterogeneity = 0.54). However, there was no significant difference in the incidence of solid tumors (including malignant melanoma) (OR: 1.28 [95% CI: 0.85-1.95]) or hematologic SPMs (OR: 1.86; [95% CI: 0.81-4.27]). In conclusion, the use of anti-CD38 mAb-based combination regimens is associated with a higher risk of non-invasive cutaneous SPMs, but not solid tumors or hematologic SPMs. The increased occurrence of non-invasive cutaneous SPMs may be due to enhanced monitoring resulting from longer treatment duration with anti-CD38 mAbs.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Primarias Secundarias / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials / Incidence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Leuk Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Primarias Secundarias / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials / Incidence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Leuk Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido